aXichem AB (AXIC-A) - Total Liabilities
Based on the latest financial reports, aXichem AB (AXIC-A) has total liabilities worth Skr9.69 Million SEK (≈ $1.04 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of aXichem AB to track the company's year-over-year net asset growth rate.
aXichem AB - Total Liabilities Trend (2008–2024)
This chart illustrates how aXichem AB's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of aXichem AB to measure how efficiently the company converts operating cash flow to free cash.
aXichem AB Competitors by Total Liabilities
The table below lists competitors of aXichem AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Greenbriar Capital Corp
V:GRB
|
Canada | CA$17.41 Million |
|
Signaux Girod
PA:ALGIR
|
France | €37.30 Million |
|
Sungwoo Techron. Co.Ltd
KQ:045300
|
Korea | ₩23.93 Billion |
|
Zamet Industry SA
WAR:ZMT
|
Poland | zł1.39 Million |
|
Jaycorp Bhd
KLSE:7152
|
Malaysia | RM54.28 Million |
|
Black Rock Mining Ltd
AU:BKT
|
Australia | AU$2.59 Million |
|
Aberforth Smaller Companies Trust PLC
LSE:ASL
|
UK | GBX75.31 Million |
|
Xavis Co. Ltd
KQ:254120
|
Korea | ₩11.92 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down aXichem AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see aXichem AB market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how aXichem AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for aXichem AB (2008–2024)
The table below shows the annual total liabilities of aXichem AB from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr4.12 Million ≈ $443.92K |
-68.18% |
| 2023-12-31 | Skr12.96 Million ≈ $1.40 Million |
-38.05% |
| 2022-12-31 | Skr20.92 Million ≈ $2.25 Million |
+745.76% |
| 2021-12-31 | Skr2.47 Million ≈ $266.24K |
+17.92% |
| 2020-12-31 | Skr2.10 Million ≈ $225.78K |
+15.34% |
| 2019-12-31 | Skr1.82 Million ≈ $195.75K |
-80.53% |
| 2018-12-31 | Skr9.34 Million ≈ $1.01 Million |
+98.77% |
| 2017-12-31 | Skr4.70 Million ≈ $505.80K |
-17.24% |
| 2016-12-31 | Skr5.68 Million ≈ $611.15K |
+23.35% |
| 2015-12-31 | Skr4.60 Million ≈ $495.46K |
-28.52% |
| 2014-12-31 | Skr6.44 Million ≈ $693.15K |
-54.66% |
| 2013-12-31 | Skr14.21 Million ≈ $1.53 Million |
+52.02% |
| 2012-12-31 | Skr9.34 Million ≈ $1.01 Million |
-30.15% |
| 2011-12-31 | Skr13.38 Million ≈ $1.44 Million |
+16.71% |
| 2010-12-31 | Skr11.46 Million ≈ $1.23 Million |
+50.42% |
| 2009-12-31 | Skr7.62 Million ≈ $820.11K |
-10.31% |
| 2008-12-31 | Skr8.50 Million ≈ $914.36K |
-- |
About aXichem AB
aXichem AB, a biotechnology company, engages in the development of natural analogue ingredients in Sweden. It offers aXivite, a natural analogue capsaicin solution for a range of dietary health applications; aXiphen-bio, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings a… Read more